



Pioneering calcium compound devices to regenerate and repair bone and soft tissue

Calcium is a vital and exciting mineral. Its applications and its use in the body are widespread.

At Biocomposites, we are distinct in that our team of specialists is singularly focused on the development of innovative calcium compounds for surgical use.

With over 25 years' experience of manipulating the surface chemistry and crystalline properties of calcium compounds, we engineer and manufacture products at the forefront of calcium technology.

Possessing unique characteristics for regenerating bone and managing dead space, our products are opening new possibilities for surgeons around the world in trauma, spine, sports injuries and musculoskeletal infections – one of the biggest healthcare challenges of the 2lst century.

At Biocomposites we are proud to be driving improved outcomes across a wide range of clinical applications for surgeons and patients alike.

Innovation is at the very heart of what we do

At Biocomposites we are proud of our series of world firsts. But we're not interested in resting on our laurels. For us, innovation is an ongoing process. Connected with universities and hospitals around the world, our continuing investment in proprietary technologies has resulted in over IOO IP grants and registrations, and positioned us at the frontier of musculoskeletal infection, trauma, spine and sports injuries.



STIMULAN®

FIRST recrystallized calcium sulfate to receive both the CE mark and clearance from the FDA.



genex®

FIRST synthetic bone-graft material with negatively charged surface chemistry to accelerate bone healing.





FIRST calcium composite device in sports injuries to receive both the CE mark and clearance from the FDA.



Exacting and consistent specifications to ensure reliable, predictable and reproducible clinical performance.

Our products are tried and trusted around the world to change lives. We believe that much of our success in over 40 countries worldwide is due to the confidence our surgeons have in our quality control.

At our state-of-the-art facility in Keele, UK, we operate to the highest international standards. Every stage of the process, from research, through manufacture to distribution, is all handled in-house—ensuring consistently high standards throughout.

We believe our dedication to quality and innovation, as well as our patented and proprietary manufacturing processes, enable us to create products of unrivaled quality and performance.


By having 100% ownership of the production process at a single site, we create an unrivaled level of confidence in our products.











- Innovative approaches to void management at infected sites
- Singular focus on calcium compound technologies
- Deep expertise
- Dedicated to quality
- Based in Keele, UK—with companies in the USA and China, and a presence in Canada and India



Our innovative calcium compound devices range from bone grafts to matrices that can be used in the presence of infection. Possessing unique characteristics for regenerating bone and managing dead space our products are opening new possibilities for surgeons around the world.

STIMULAN®

New calcium sulfate recrystallized for use in the presence of infection

genex®

An innovatove, versatile calcium compound that supports natural healing, then vanishes without a trace.



Highly consistent, polycrystalline and porous calcium phosphate bone substitute for use in trauma and spine.

Biosteon®

Osteoconductive calcium phosphate composite with improved strength retention and bone-bonding potential.



First synthetic calcium composite arthroscopic device to receive CF mark and FDA clearance

Find out more at biocomposites.com

© 2017, Biocomposites, STIMULAN, Bilok, genex, Allogran, Biosteon and bringing calcium to life are registered trademarks of Biocomposites Ltd. All rights reserved. No unauthorized copying, reproduction, distributing or republication is allowed unless prior written permission is granted by the owner, Biocomposites Ltd.

Patents granted EP I390086 BI, US 8632796, CN ZL02809I94.9, US 8496955, GB2367552, EP I204599 BI, US 678039I, EP I4360I9 BI, US 8563024, CN ZL02825I34.2, EP 259423I BI, US 8883063, CN ZL20I2I0466II7.X, GB24967I0, EP 259423I BI

Patents pending GBI502655.2, EP I6I542I05, US I5/040075, CN 20I6I00897I0.5, US I5/288328

MAOII2R2



